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One-time general consent for research on biological samples
Opt out system for patients is optimal
and endorsed in many countries
Editor—Wendler’s valuable overview of
empirical studies of patients’ preferences
about the use of residual (leftover) tissue for
research is not complete.1 The discussion
has already been settled by legislation in
many countries.
In 2004 the Danish act on patient rights
was amended with an opt out system for
using residual tissue for research. In 2004
the US Office for Human Research Protec-
tions (OHRP) issued guidance that research
on residual tissue which is anonymous to the
researcher is not human subject research
and therefore the tissue can be used without
consent.2 Earlier the Dutch Federation of
Medical Research Societies’ code of conduct
on research with residual tissue drafted with
patients’ organisations had an opt out
system for research on samples anonymous
to the researcher.3 In the recent UK Human
Tissue Act no form of consent is needed for
the use of fully anonymous or coded (or
linked) residual tissue that is anonymous to
the researcher, provided that an ethical
review board has permitted the study. The
more restrictive provisions in the original
bill were amended also because of pressure
from patient groups afraid that research to
their benefit would be hampered by the pro-
posed consent system.
Wendler emphasises autonomy and
argues that one-time consent protects the
autonomy of individuals and
protects them from serious
risks. There are two major
arguments against this.
Firstly, autonomy should be
balanced against other val-
ues such as the interests of
patients who might benefit
from this research.4 Sec-
ondly, autonomy as such
cannot protect individuals
from risks but only from risks
they do want to carry.
Research on residual tissue,
whether anonymous or
anonymously used and being
coded, does not carry any risks to individu-
als. Ethical review boards should oversee
that sufficient measures have been taken to
ensure that the samples used in research
remain anonymously used. It should be pos-
sible to enrich data from tissue research with
patient data. Fully anonymising samples, as
suggested by Wendler, is a waste of valuable
information.5
Jan Willem W Coebergh professor of cancer surveillance
j.coebergh@erasmusmc.nl
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Centre, Box 2040, 3000 CA Rotterdam, Netherlands
Evert-Ben van Veen lawyer
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Good idea, but will it happen?
Editor—Wendler’s advocacy of one-time
consent for research use of biological
samples that would otherwise
be discarded as clinical waste
is welcome and would be
ethically sound and finan-
cially efficient.1 But this sug-
gestion is not new. The Royal
College of Pathologists advo-
cated exactly this five years
ago, at the height of the
organ retention controversy,
stating that in relation to
tissue removed from living
patients: “we suggest that as a
minimum it should be possi-
ble to record consent or
objection to ‘generic’ research
use, as outlined above, and to teaching and
quality control. Consent or objection should
be assumed to refer to all samples from that
patient, unless otherwise specified.”2
However, the college also stated that it
was “gravely concerned about implementa-
tion, and the speed at which it will occur. We
believe it highly unlikely that NHS trusts will
act with sufficient urgency . . . We therefore
urge the Departments of Health to distrib-
ute appropriate instructions.”
Since then the introduction of the
Human Tissue Act 2004 puts the onus on
researchers to obtain consent, even for tissue,
blood, and urine which would otherwise be
disposed of as waste, even though the
patients concerned have usually gone home
long before the need for consent is
recognised. The act does permit the use of
tissue in research without consent, but only if
samples are anonymised (which makes
crucial clinical correlation difficult or impos-
sible) and if a research ethics committee has
approved (and experience suggests that
many such committees will regard this as
inappropriate and demand consent anyway).
The college showed that to ask for
consent every time a sample is taken would
be absurdly expensive and that staff not
involved in research would not do it. So it
argued for one-time consent during the
development of the act—without success. It is
not part of the act. It has not been advocated
by the Department of Health or (yet) by the
new Human Tissue Authority. But no
workable alternative has been proposed.
As Wendler shows, the autonomous wish
of the vast majority of patients is that their
surgical waste should be available for the
benefit of mankind, rather than being incin-
erated. At present, most patients are never
asked, so this wish is ignored.
Failing to ask empowers no one. Is such
disrespect for patient autonomy not an ethi-
cal outrage?
Peter N Furness consultant histopathologist
Leicester General Hospital, Leicester LE5 4PW
pnf1@leicester.ac.uk
Competing interests: PNF is a histopathologist
and chaired the working group which wrote the
royal college report cited.
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facilitate changes in procedures for handling ‘surplus’ and
archival material from human biological samples. 2001.
www.rcpath.org/resources/pdf/transitional.pdf (accessed
3 Mar 2006).
Autonomy and majority rules have been
misunderstood
Editor—Wendler suggests that since most
(79-95%, depending on the study) people
were willing to provide a one-time general
consent to further usage of their biological
sample we should routinely include a
request for the subject to consent to the
further indefinite usage of their samples in
consent forms and participant information
sheets.1
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This misconstrues the nature of
autonomy by conflating it with majoritarian
democracy. Simply because most people
would hypothetically consent to something
does not mean doing that thing is part of
respecting autonomy.
Autonomy is about respecting the
individual’s right to choose for himself or
herself—typically taken to be the basis for
the requirement of informed consent.2 Its
two elements are having sufficient informa-
tion to make the decision well, and being
competent to make that decision.
This seems to require full and appropri-
ate information about what will be done
with the samples. Thus the real debate
ought to be whether a one off indefinite
consent can genuinely be considered to
be valid consent. Is consent given in these
circumstances genuine consent? This
debate matters from the point of view of
autonomy, not whether people are happy to
give their consent.
Imagine if a researcher presented a medi-
cal study asking participants to participate
without telling them what was being studied.
In almost any other circumstances we
would not accept as competent someone
who consents to participate in research
without knowing what is being studied or
what the expected or hoped for outcomes
are. There seems no reason to believe that
people are more competent to decide what
should happen to their biological samples,
without any knowledge of what is being
done with them.
Finally, implicit in the high rate of
consent for indefinite research may be that
people tacitly understand the research to be
only for medical purposes. The rates of con-
sent are likely to plummet if it was pointed
out to participants that their blanket consent
could lead to their samples being used to
develop chemical or biological weapons, to
take an extreme example.
David Hunter lecturer in bioethics
School of Biomedical Sciences, University of Ulster,
Coleraine, Londonderry BT52 1SA
d.hunter3@ulster.ac.uk
Competing interests: DH sits on one of the
Office for Research Ethics Committees in
Northern Ireland Health and Personal Social
Services, as well as the University of Ulster
Research Ethics Committee.
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Harmful impact of EU clinical
trials directive
Trial of alerting drug in fibromyalgia has
had to be abandoned . . .
Editor—Hemminki and Kellokumpu-
Lehtinen show the impact of the EU
Clinical Trials Directive and the resulting
additional cost and bureaucratic delays on
cancer drug research.1 It has become almost
impossible for academic researchers to
initiate and conduct pharmaceutical trials
without the involvement of a pharmaceuti-
cal company, particularly in areas that do
not attract much funding or involve a drug
that is close to the end of or outwith patent
protection.
We recently abandoned attempts to con-
duct a trial of an alerting drug in patients
with fibromyalgia. The Trials Directorate of
the Medicines and Healthcare products
Regulatory Agency (MHRA) was as helpful
as possible within the limits of the regula-
tions, but the cumulative burden of regula-
tory requirements and delays, both locally
and nationally, resulted in the modest grant
from the pharmaceutical company being
almost exhausted before we could even
begin to contemplate the recruitment of a
single patient.
We endorse the authors’ plea that these
regulations, and their national implementa-
tion, are harming the very group they were
designed to protect, and should be amended
as a matter of urgency.
Christopher D Hanning consultant in sleep medicine
Patricia Rentowl research assistant
Leicester General Hospital, Leicester LE5 4PW
chris.hanning@uhl-tr.nhs.uk
Competing interests: None declared.
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. . . and so has trial of melatonin in cancer
related weight loss . . .
Editor—The editorial by Hemminki and
Kellokumpu-Lehtinen on the harmful
impact of the EU Clinical Trials Directive
highlights important issues that need to be
addressed before investigator led cancer
research becomes a thing of the past.1
The directive was supposed to protect
patients by minimising biasing influences
on clinical studies. The reality is that it has
made it all but impossible to carry out
researcher led studies without the financial
and logistical backing of the pharmaceuti-
cal industry.
We recently successfully negotiated the
new and long EU research directive road,
through the process of clinical governance,
sponsorship, and ethics approval to run a
double blind placebo controlled trial of
melatonin in cancer related weight loss.
Unfortunately, after 18 months our research
quest had to be abandoned because the
directive decreed that we needed to have an
investigational medicinal product licence.
This was not stipulated at the start of the
process.
Without the support of a pharma-
ceutical company we were unable to secure
such a licence. Presumably the potential for
profit from a cheap product such as
melatonin is limited. I suspect that other
researchers looking to investigate medicinal
products for which there may be limited
commercial potential may meet similar
difficulties. This poses the question: by
trying to improve the quality of clinical
research and safeguard patients, how much
bias has the EU directive introduced to
clinical studies to the detriment of the same
patients the directive is supposed to be
safeguarding?
Max Watson research fellow
Belfast City Hospital, Belfast BT9 7AB
alimaxuk@yahoo.com
Competing interests: None declared.
1 Hemminki A, Kellokumpu-Lehtinen P-L. Harmful impact
of EU clinical trials directive. BMJ 2006;332:501-2.
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. . . while paediatric oncology is being
scuppered
Editor—The editorial by Hemminki and
Kellokumpu-Lehtinen is a startling summary
of the impact of the EU Clinical Trials Direc-
tive and the associated national legislation on
the conduct of investigator led research.1 It is
remarkable how little response or debate has
emerged since the introduction of this
directive: every investigator with whom I have
discussed its impact complains about increas-
ing bureaucracy and associated costs.
Paediatric cancer, by its nature, involves
only small numbers of patients and relies
almost exclusively on investigator led trials.
Over the past few decades, there have been
major advances in the outcomes for children
with leukaemia and Wilms’ tumour, to
choose but two conditions. In the past nearly
all children in the United Kingdom with
such conditions were included in a clinical
trial. Now, however, the financial and admin-
istrative burden that has recently been
inflicted is beginning to erode the tradition-
ally high rates of recruitment to paediatric
cancer trials. Should this process continue it
will become impossible to complete such
trials in a timely fashion and treatment will
cease to evolve.
If the goals of the EU Clinical Trials
Directive were to improve the protection of
patients, the reliability of research reporting,
and to harmonise and increase the competi-
tiveness of European clinical research, the
directive is clearly failing to achieve any of its
stated objectives. And further directives are
to be expected. All of us involved in
investigator led research of this type need to
lobby our representatives to have the
current legislation amended.
Christopher D Mitchell consultant paediatric
oncologist
John Radcliffe Hospital, Oxford OX3 9DU
chris.mitchell@paediatrics.ox.ac.uk
Competing interests: None declared.
1 Hemminki A, Kellokumpu-Lehtinen P-L. Harmful impact of
EU clinical trials directive. BMJ 2006;332:501-2. (4 March.)
Who will fund hypothesis
testing studies?
Editor—Although Loke et al concluded
that case reports in pharmacovigilance have
limited value,1 case reports or series are
valuable as hypothesis generating papers,
which benefit clinicians and patients. The
number of follow-up studies is only one out-
come by which to judge the value of case
reports or series, but other outcomes may be
more difficult to study.
Letters
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Although case reports are valuable in
pharmacovigilance, hypothesis testing studies
are necessary and I agree with Vanden-
broucke that a more consistent scheme is
needed.2 An important question is, where will
funding for such studies come from? Phar-
maceutical companies may have little incen-
tive to further investigate adverse reactions
and if funding is provided there may be con-
flicting interests. For different reasons, gov-
ernments may also be reluctant to fund
pharmacoepidemiology studies.3
In New Zealand, the government funded
intensive medicines monitoring programme
(IMMP) performs hypothesis-testing studies
which further investigate adverse drug
reactions, including calculating incidence
and identifying patients at risk.4 The pro-
gramme was established in 1977, when it was
recognised that spontaneous reports were
insufficient to detect and fully evaluate
adverse drug reactions. In its almost 30 year
history, the programme has performed
many valuable studies and is internationally
respected,3 yet its future remains uncertain.
None of the staff has a contract beyond 30
June 2006. It is still not known how the pro-
gramme will contribute to the new Australia
New Zealand Therapeutic Products Agency
(www.tgamedsafe.org). In the meantime,
important pharmacoepidemiology studies
are at risk of not being completed, with loss
of valuable data contributed over many years
by patients and doctors throughout New
Zealand. The agreement that hypothesis test-
ing studies are required as a component of
pharmacovigilance must be backed by a
commitment to fund such work adequately.
Mira Harrison-Woolrych director
Intensive Medicines Monitoring Programme,
University of Otago, Dunedin, New Zealand
Mira.harrison-woolrych@stonebow.otago.ac.nz
Competing interests: MHW is director of the
New Zealand intensive medicines monitoring
programme.
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survey of follow-up. BMJ 2006;332:335-9. (11 February.)
2 Vandenbroucke JP. Case reports of suspected adverse
reactions. BMJ 2006;332:488. (25 February.)
3 Herxheimer A. Open letter to Annette King, Minister of
Health New Zealand. BMJ 2004;329:51.
4 Harrison-Woolrych M, Coulter DM. PEM in New Zealand.
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ester: Wiley, 2006.
LIFT study is discontinued
Editor—We informed the BMJ about the
increased risk of stroke in the long term
intervention on fractures with tibolone
(LIFT) study.1 Further analysis now indicates
a benefit of tibolone on risk of vertebral
fracture, the primary end point of the study.
Thus, the LIFT study is being stopped
because of a recommendation by the data
safety monitoring board that the trial has
reached its objectives and additional
follow-up is unlikely to provide further
information about other adverse events.
LIFT is a randomised clinical trial
designed to determine the effect of treatment
with tibolone on risk of vertebral fracture in
postmenopausal women with osteoporosis.
Altogether 4538 postmenopausal women
with a bone mineral density T score at the
total hip or spine equal or lower than − 2.5
without a fracture or a T score of − 2.0 with a
fracture were assigned to 1.25 mg tibolone or
placebo. The average age of participants was
68 (SD 5.2) years. They are followed up peri-
odically for clinical outcomes and safety. The
trial started in 2001 and the primary
outcome analysis is scheduled for June 2006.
A data safety monitoring board periodi-
cally reviews the unblinded results. A
steering committee, whose voting members
are investigators independent of the spon-
sor, Organon, oversees scientific issues. The
data safety monitoring board has previously
notified the sponsor and steering committee
of an increased risk of stroke during an
average of 2.4 years of the trial with a hazard
ratio of 2.591. The updated results (at 2.75
years) for stroke (ischaemic plus haemor-
rhagic) and vertebral fractures (based on a
semi-quantitative reading of the radio-
graphs) for tibolone and placebo groups
were respectively 25 (1.11%) and 11 (0.49%)
(hazard ratio 2.3 (P = 0.02)) and 44 (2.1%)
and 85 (4.1%) (hazard ratio 0.5 (P = 0.0003)).
The data safety monitoring board has
recommended to us that the study be
discontinued and that dispensation of all
study treatments to subjects be ended as
soon as practicable. We have concurred and
plan to publish a more detailed report.
Steven R Cummings director
California Pacific Medical Center, San Francisco,
CA 94105, USA
scummings@sfcc-cpmc.net
On behalf of the LIFT Steering Committee
Competing interests: SRC is consultant and has
received research funding from Organon.
1 Grobbee DE, LIFT Steering Committee. LIFT study to
continue as planned. BMJ 2005;331:843.
Stress and illness: call to action
Editor—The prospective study by Chandola
et al on chronic stress at work as a risk factor
for the metabolic syndrome adds a further
public health imperative to reduce the signifi-
cant morbidity from chronic stress at work.1
Last month a BUPA insurance survey
found that seven million Britons feel so ill
with “worry” that they seek medical help.2 In
the employed population the British Occu-
pational Health Research Foundation found
that the largest, and growing, cause of work
related ill health is now mental ill health.3
A number of remedial interventions
such as cognitive behaviour therapy have
been looked at, generally in individual sick
employees. In terms of the social gradient of
illness described among civil servants,1 indi-
vidual interventions worked best with
employees in high-control jobs.3 Employers
have a legal duty of care to protect the
health of all their employees, and the Health
and Safety Executive has published manage-
ment standards aiming to reduce stress at
work.4 In terms of reducing chronic stress, it
may help to consider change at the level of
positive wellness for the whole organisation,
perhaps using a social engagement model
with dynamic learning-in-action.5
Woody Caan professor of public health
Anglia Ruskin University, Chelmsford CM1 1SQ
a.w.caan@anglia.ac.uk
Competing interests: WC is currently a minor,
local collaborator in a large national Health and
Safety Executive project for tackling work related
stress.
1 Chandola T, Brunner E, Marmot M. Chronic stress at work
and the metabolic syndrome: prospective study. BMJ
2006;332:521-4. (4 March.)
2 BUPA. Seven million Brits are making themselves ill with
worry. http://www.bupa.co.uk/about/html/pr/150206_
worried_britons.html (accessed 9 Mar 2006).
3 British Occupational Health Research Foundation.
Workplace interventions for people with common mental health
problems: Evidence review and recommendations. London:
BOHRF, 2005.
4 International Stress Management Association. Working
together to reduce stress at work. Sudbury: HSE Books, 2004.
5 Hillier D, Fewell F, Caan W, Shephard V. Wellness at work:
enhancing the quality of our working lives. Int Rev Psychia-
try 2005;17: 419-31.
Alcohol use disorders
identification test has bias
Editor—In the brave new world of a
National Health Service where value for
money is tantamount, Coulton et al are to be
commended for using several valid clinical
outcome measures for alcohol misuse and
dependence and comparing them with
more traditional biochemical variables com-
monly used in both primary and secondary
care.1 However, some caution is required in
interpreting their results in light of the
methodology.
Firstly, the alcohol use disorders identifi-
cation test (AUDIT) is made up of questions
that assess aspects of alcohol use such as
quantity or frequency and dependence.
Therefore its internal validity when meas-
ured against outcomes such as binge drink-
ing and alcohol dependence is likely to be
high in ROC (receiver operating character-
istic) analyses. A more clinically meaningful
outcome for primary care may be the
presence of problems consequent on drink-
ing, which could have been ascertained
using a rating scale such as the drinking
problems index.2
Secondly, the selection of male drinkers
is a major source of bias, as traditional
screening tools such as AUDIT show low
sensitivity in detecting alcohol misuse in
women and older people.3 4 The study by
Coulton et al would need further replication
in both these populations, as well as in inner
city areas, where populations show greater
cultural diversity.
Although this paper was an important
contribution to detecting and screening
alcohol use disorders in primary care,
clinicians should be mindful of the wider
population, or the general public may be
misinformed in the same way as it was with
the public health message of alcohol and
cardioprotection, which, again, only applies
to a section of the population.
Rahul Rao consultant
York Clinic, Guy’s Hospital, London SE1 3RR
tony.rao@kcl.ac.uk
Competing interests: None declared.
Letters
667BMJ VOLUME 332 18 MARCH 2006 bmj.com
1 Coulton S, Drummond C, James D, Godfrey C, J Bland JM,
Parrott S, et al. Opportunistic screening for alcohol use
disorders in primary care: comparative study. BMJ
2006;332:511-7. (4 March.)
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Where patients with cancer die
in Cuba
Editor—Gomes and Higginson show that
identifying the factors influencing where
terminally ill patients with cancer die is
complicated.1
In 1981-2 we studied 13 105 deaths in
adults (>15) in three different Cuban
provinces. Only 27.0% of adult deaths due
to malignant tumours occurred outside
hospitals in Ciudad de La Habana, a
western province that includes the capital of
Cuba, compared with 60.2% in Cienfuegos,
in the centre and southern part of the
island, and 58.2% in Las Tunas, in the east-
ern side. The people who died at home
were older than those in hospital, were
found less in urban areas, and showed no
variation by sex.2
We then studied adult mortality in the
same three Cuban provinces over 10 years
from 1990 to 1999. There were 36 999
deaths due to malignant tumours in Ciudad
de La Habana (19.3% of all deaths), 5269 in
Cienfuegos (19.9%), and 5820 in Las Tunas
(21.6%). The mean ages were 67.9 (14.6)
years, 67.9 (15.9), and 66.1 (16.6), respec-
tively. Only 28.3% died at home in Ciudad
de La Habana compared with 61.8% in
Cienfuegos and 34.4% in Las Tunas.3
We recently carried out another study in
Cienfuegos City, the capital, to investigate
why so many more patients with cancer die
at home in Cienfugos (unpublished data).
We interviewed the relatives or proxies of a
randomised sample of 226 adults (>15) who
had lived in the city and died in 2003.Of 171
who were classified as terminally ill, 91
(53%) had died at home—in 58% of cases
because of the patient’s or relatives’ choice.
For the last years of the past decade we
have implemented a comprehensive pro-
gramme of palliative care in primary care in
Cienfuegos. The high proportion of deaths
at home in patients with cancer could be
related to this new service.4 Even in a highly
organised national health system such as
Cuba’s—universal, accessible, equitable, and
free to all—looking for local answers to spe-
cific conditions seems to be effective.5
Alfredo A Espinosa-Roca coordinator, palliative care
programme
Municipal Health Division of Cienfuegos,
Ave 56 No 2917 altos, Cienfuegos 55100, Cuba
espinosa@perla.inf.cu
Alfredo D Espinosa-Brito professor
Eduardo Fernández-Casteleiro doctor
Teresita Sabatés-Llerandi doctor
Teaching Hospital “Dr Gustavo Aldereguia Lima,”
Cienfuegos, Ave 5 de Septiembre and Calle 51A,
Cienfuegos 55100
Competing interests: None declared.
1 Gomes B, Higginson IJ. Factors influencing death at home
in terminally ill patients with cancer: systematic review.
BMJ 2006;332:515-21. (4 March.)
2 Espinosa A, Diez E, González E, Santos M. Adultos falleci-
dos en tres provincias cubanas (1981-1982). Algunos
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muerte. Rev Cub Salud Pública 1989;15:245-58.
3 Espinosa A, Quintero Y, Cutiño Y, Romero AJ, Bernal JL.
Mortalidad del adulto en tres provincias cubanas. In :
Iñiguez L, Pérez OE. Heterogeneidad social en la Cuba actual.
Havana: Ciudad de La Habana, Centro de Estudio de
Salud y Bienestar Humano, Universidad de La Habana,
2004:163-94.
4 Espinosa AA, Romero AJ, Misas M, Fresneda O. Asistencia
al enfermo terminal en la atención primaria de salud. Rev
Finlay 2005;10 (número especial):133-43.
5 Murray SA, Boyd K, Thomas K, Higginson IJ. Developing
primary palliative care. BMJ 2004;329:1056-7.
Diagnosis and treatment of
multiple sclerosis
Potential changes in management for
clinically isolated episode
of optic neuritis
Editor—Murray highlights
the recent advances in diag-
nosis and management of
multiple sclerosis.1 This is
particularly important in
managing a clinically iso-
lated episode of optic
neuritis. Current UK
ophthalmological manage-
ment of a unilateral episode
of typical optic neuritis is
generally not to investigate
or to treat.2 However, with
the development of the McDonald criteria
for diagnosing multiple sclerosis and
advances in magnetic resonance imaging of
lesions,3 4 there is potential for early diagno-
sis of multiple sclerosis.
This is important as new treatments
such as recombinant interferon beta-1a may
reduce the development of clinically definite
multiple sclerosis.5 Future best clinical
practice in the management of acute optic
neuritis may therefore be to investigate all
patients to identify those with multiple
sclerosis who would benefit from early treat-
ment.
Peter D Cackett ophthalmology specialist registrar
pete@pdcackett.demon.co.uk
James Cameron ophthalmology senior house officer
Harry Bennett ophthalmology consultant
Princess Alexandra Eye Pavilion, Edinburgh
EH3 9HA
Competing interests: None declared
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Evaluation of the management of optic neuritis: audit on
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3 McDonald WI, Compston A, Edan G, Goodkin D, Hartung
HP, Lublin FD, et al. Recommended diagnostic criteria for
multiple sclerosis: guidelines from the international panel
on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:
121-7.
4 Magnetic resonance imaging advances in multiple sclero-
sis. J Neuroimaging 2005;15(suppl):5-9S.
5 Soderstrom M. Multiple sclerosis: rationale for early treat-
ment. Neurol Sci 2003;24 (suppl 5):S298-300.
Ocular manifestations of multiple sclerosis
Editor—Murray reviewed the diagnosis
and treatment of multiple sclerosis.1 Ocular
manifestations are sometimes the first sign
of the disease, including optic neuritis,
internuclear ophthalmoplegia, ocular
motor cranial nerve palsies, trigeminal and
facial nerve palsies, nystagmus, pars planitis,
and retinal periphlebitis.2 These conditions
may predict additional demyelinating
events.
The optic neuritis treatment trial is a
randomised 15 centre trial of 457 patients
to assess the effects of corticosteroids in
optic neuritis.3 4 The results showed that
intravenous methylprednisolone hastened
the recovery of visual function after optic
neuritis without significantly improving the
long term final visual acuity. The trial also
showed that while intravenous steroids
reduced the incidence of symptomatic mul-
tiple sclerosis, oral steroids were associated
with an increased recurrence
of optic neuritis.
The treatment of inter-
mediate uveitis due to multi-
ple sclerosis is indicated
when the visual acuity is 6/12
or less due to cystoid macular
oedema. This includes sys-
temic and posterior sub-
Tenon steroids, cryotherapy,
and pars plana vitrectomy.5
Symptomatic patients
with longstanding ocular
motility disorders and ocular
cranial nerve palsies may
benefit from prisms or corrective surgery on
extraocular muscles.
Mohammad T Masoud senior house officer,
ophthalmology
Stirling Royal Infirmary, Stirling FK8 2AU
seham_tm@hotmail.com
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Postnatal economic burden of
limited karyotyping
Editor—Chitty et al suggest a strategy to
identify chromosomal abnormalities that
relies on quantitative fluorescent polymer-
ase chain reaction (qf-PCR) and full
karyotyping only in cases of fetal nuchal
translucency thickness > 4 mm, as opposed
to full karyotyping of all chorionic villous
samples.1 Eliminating double testing results
in an upfront economic savings of about
£1.5m (€2.17m; $2.50m) distributed across
17 479 pregnancies. However, such an
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approach has a failure rate of 1%, the
economic consequences of which Chitty et
al do not appreciate in their discussion.
The incremental lifetime economic cost
incurred by an infant born with trisomy 21 is
about £350 000 (adjusted for 2006 cur-
rency).2 Considering only chromosomally
abnormal babies that came to term as well as
those undetected by limited karyotyping,
and given a reasonable termination rate of
70%, the six babies that would have been
missed in the study alone represent an eco-
nomic cost of £2.1m.
Assuming 640 000 yearly births in Eng-
land and Wales,3 and the necessity for chori-
onic villous sampling in about 6% of
pregnancies,4 we estimate that a shift from
full karyotyping to the approach suggested
by Chitty et al will result in a systemic
economic loss of over £5.3m (that is,
incremental costs of infants born with
trisomy 21 minus savings from limited
karyotyping) each year. This is not to ignore
the externalities and intangible costs that
may be brought about by missed cases of
chromosomal abnormality. It may be worth
shouldering upfront testing costs to provide
truly accurate information to mothers, and
avoid much greater subsequent societal
economic burden.
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Physiological-social scoring is
important in pandemic flu
Editor—Barlow argues that prognostic
assessment will be important in a flu
pandemic.1 Although the predictive tools
CURB-65 and CRB-65 have been validated
in terms of 30 day mortality,2 their
limitations with respect to prediction of
mortality have recently been highlighted.
Their value as a track and triage tool has not
been established.
This is of prime importance as the num-
bers of presentations expected during a flu
pandemic require that an instrument be
developed which recognises the physiologi-
cal derangement and social and comorbid
factors which normally influence hospital
admission criteria. Ideally, this tool would be
applicable across the health economy and
amenable to use in primary and secondary
care by medical, nursing, and allied health
professionals.
Given the magnitude of a pandemic (we
calculate that attendances at our emergency
department may be in excess of 600% of
normal3), it is imperative that any clinical
guidance recognises that degradation with
scale will occur as the pandemic progresses.
We therefore suggest that any triage tool
should be scalable in terms of admission
threshold.
Using the principle that physiological
parameters deteriorate for several hours to
days before catastrophic decompensation,
we suggest that a modification of the
previously published medical early warning
score will provide a useful triage tool to
identify those in need of admission and
reassure those fit to self care at home.4
The modification addresses comorbid and
social factors. We discuss the validation of
our tool in the European Respiratory
Journal.5
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GPs provide valuable continuity
during age transition
Editor—We support the key elements of
transitional care between adult and paedi-
atric care advocated by McDonagh and
Viner.1 However, they did not discuss the
role of the general practitioner (GP) in man-
aging chronic illness during and after transi-
tion. General practitioners play a central
part in coordinating care after transition and
are well placed to help provide continuity of
care.
We conducted a small survey of carers of
people with profound and multiple learning
disabilities in Scotland. Carers were notice-
ably more dissatisfied by care on transition
to adult services, failure of coordination of
care being a central factor. In our follow-on
survey of general practitioners in Lothian 65
of the 100 who responded to the question-
naire thought that they did not have
adequate training to assess and treat people
with profound and multiple learning dis-
abilities, and 63 thought that they would
benefit from additional training.
With an ever increasing number of gen-
eral practitioners with special interests in
specific chronic diseases, the possibility of
training general practitioner specialists to
help manage transition and beyond is
appealing. We found an encouraging
number of general practitioners (16 of those
who replied) were interested in undergoing
such specialist training.
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The importance of being
naked from the elbow down
Editor—In the neonatal intensive care unit
we demand that all staff remove their jewel-
lery at the beginning of each shift. Anyone
wearing a watch or dress ring is deemed not
to have washed his or her hands. “Naked
from the elbows down” is the expression in
common usage. Visiting surgeons and all
other disciplines now comply with our
regulations.
It was therefore with some disappoint-
ment that I viewed the cover photograph of
the BMJ of 4 March showing a mother
squatting in labour (above).1 The midwife’s
watch on her left wrist is disappearing into
the groin of the labouring woman.
When will we take this subject seriously?
Ian A Laing consultant neonatologist
Simpson Centre for Reproductive Health,
Edinburgh EH16 4SU
ian.laing@luht.scot.nhs.uk
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